Resources

This fact sheet describes a phase 3 clinical study that PATH and our partners are conducting in Senegal to evaluate the clinical efficacy of a seasonal, trivalent live attenuated influenza vaccine (LAIV). By providing evidence on how well this type of vaccine works among young children in Senegal, this study will help inform efforts in the scientific community to develop optimal LAIVs for the world’s most vulnerable children, as well as policy decisions for potential future LAIV use in Senegal and other tropical, low-resource countries in Africa.

This operational assessment of Sayana® Press in Uganda examines the extent to which Sayana® Press facilitates the logistics of managing and administering injectable contraception and assesses whether providers in Uganda find benefits in this new presentation.

At the 2013 Women Deliver Conference in Kuala Lumpur, Elizabeth Abu Haydar—a PATH public health specialist—presented an overview of PATH’s work activities on the non-pneumatic antishock garment in a workshop discussing local manufacturing and logistics.

This issue of Directions in Global Health features work by OneWorld Health, PATH’s drug development program, to lead development of innovative methods to enhance the supply of artemisinin, a key ingredient in malaria treatments. It includes a commentary by Dr. Ponni Subbiah, who directs PATH’s drug development efforts. Other articles cover work to improve cervical cancer screening, protect infants from respiratory syncytial virus, increase access to family planning, and strengthen and expand use of human milk banking.

This issue of PATH Today describes PATH's multipronged approach to eliminating malaria in Africa and the development of semisynthetic artemisinin, a key ingredient in malaria treatment. It includes updates on PATH's work to prevent diarrhea in Cambodia and to diagnose cervical cancer. It also contains a profile of Dean Allen, CEO of McKinstry and PATH's board treasurer.